Lab
Quest Diagnostics of Pennsylvania INC.
Quest Diagnostics of Pennsylvania INC. was paid $20.20M by Medicaid between Jan 2018 and Dec 2024, across 263 billing codes. Its largest line is 82306, Vitamin D; 25 hydroxy, includes fraction(s), if performed — 7.0% of everything it billed.
33Billing provider infoQUEST DIAGNOSTICS OF PENNSYLVANIA INC.
BUFFALO, NY 14228
BUFFALO, NY 14228
33aNPI1366460321assigned 07/18/2006
33bProvider typeClinical Medical Laboratory
28Total paid$20.20M
24GClaims1,460,970
24DCodes billed263
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in New York
Rank by total paid#17 of 116
Median peer was paid$618K
This provider vs. median33×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official BOWLES, CHARLES controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 208,176 | $2.31M | |
| 2019 | 187,546 | $2.29M | |
| 2020 | 184,122 | $2.79M | |
| 2021 | 217,428 | $3.39M | |
| 2022 | 221,677 | $3.22M | |
| 2023 | 237,669 | $3.31M | |
| 2024incomplete | 204,352 | $2.89M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 7.0% | 37,787 | 37,660 | $1.42M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 6.6% | 16,356 | 15,292 | $1.34M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 5.7% | 49,811 | 48,703 | $1.15M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 5.6% | 49,078 | 47,991 | $1.14M |
| 80053 | Comprehensive metabolic panel | 5.3% | 104,854 | 102,282 | $1.07M |
| 84443 | Thyroid stimulating hormone (TSH) | 3.4% | 75,806 | 75,120 | $697K |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | 2.8% | 682 | 681 | $558K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 2.8% | 11,571 | 11,567 | $556K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 2.7% | 24,327 | 23,875 | $539K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.6% | 68,532 | 46,713 | $523K |
| 83036 | Hemoglobin; glycosylated (A1C) | 2.5% | 46,284 | 46,122 | $504K |
| 80061 | Lipid panel | 2.3% | 77,383 | 77,097 | $472K |
251 more codes
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 2.3% | 13,311 | $460K |
| 84439 | 1.9% | 41,769 | $386K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1.8% | 18,688 | $356K |
| 86480 | 1.7% | 6,651 | $343K | |
| 87536 | 1.6% | 2,755 | $331K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 96,547 | $313K |
| 82607 | 1.5% | 24,278 | $311K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.4% | 34,027 | $285K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.3% | 1,944 | $261K |
| 84403 | 1.2% | 6,962 | $245K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.2% | 9,828 | $241K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.1% | 15,480 | $230K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 1.1% | 604 | $217K |
| 87088 | 1.0% | 21,485 | $207K | |
| 82728 | <1% | 13,109 | $198K | |
| 84153 | <1% | 7,919 | $193K | |
| 86803 | <1% | 18,416 | $189K | |
| 82746 | <1% | 14,263 | $183K | |
| 83013 | <1% | 1,527 | $147K | |
| 84402 | <1% | 4,302 | $135K | |
| 87070 | <1% | 15,911 | $134K | |
| 87522 | Neg quan hep c or qual rna | <1% | 2,200 | $133K |
| 86003 | <1% | 1,864 | $122K | |
| 82670 | <1% | 3,278 | $117K | |
| 87340 | <1% | 10,181 | $116K | |
| 83655 | <1% | 7,316 | $113K | |
| 83001 | <1% | 4,852 | $110K | |
| 83970 | <1% | 2,080 | $110K | |
| 88142 | <1% | 4,172 | $106K | |
| 84146 | <1% | 3,851 | $104K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 13,557 | $99K |
| 81001 | <1% | 24,108 | $99K | |
| 87077 | <1% | 8,866 | $91K | |
| 82784 | <1% | 5,084 | $86K | |
| 83002 | <1% | 3,837 | $82K | |
| 84702 | <1% | 6,410 | $81K | |
| 86376 | <1% | 5,058 | $78K | |
| 87481 | <1% | 2,753 | $76K | |
| 86762 | <1% | 4,399 | $75K | |
| 82570 | <1% | 14,520 | $74K | |
| 86780 | <1% | 5,617 | $74K | |
| 86769 | <1% | 1,922 | $74K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,407 | $73K |
| 83540 | <1% | 14,107 | $73K | |
| 83550 | <1% | 12,818 | $66K | |
| 87186 | <1% | 9,377 | $65K | |
| 82043 | <1% | 12,470 | $64K | |
| 86235 | <1% | 2,615 | $59K | |
| 86696 | <1% | 3,043 | $54K | |
| 80349 | <1% | 10,736 | $54K | |
| 86800 | <1% | 3,879 | $53K | |
| 85027 | <1% | 15,985 | $52K | |
| 86360 | <1% | 784 | $52K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 1,246 | $50K |
| 86706 | <1% | 4,763 | $49K | |
| 87081 | <1% | 8,779 | $47K | |
| 80348 | <1% | 9,283 | $46K | |
| 86765 | <1% | 2,998 | $45K | |
| 86160 | <1% | 2,019 | $44K | |
| 86140 | <1% | 10,435 | $44K | |
| 86704 | <1% | 4,129 | $43K | |
| 84144 | <1% | 1,809 | $43K | |
| 86592 | <1% | 11,802 | $40K | |
| 86038 | <1% | 7,436 | $39K | |
| 80362 | <1% | 7,596 | $38K | |
| 82627 | <1% | 1,566 | $38K | |
| 84154 | <1% | 1,433 | $35K | |
| 87631 | <1% | 325 | $33K | |
| 86708 | <1% | 3,144 | $32K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 244 | $31K |
| 84436 | <1% | 5,286 | $31K | |
| 86787 | <1% | 2,988 | $30K | |
| 84450 | <1% | 5,737 | $29K | |
| 83525 | <1% | 2,228 | $29K | |
| 85652 | <1% | 13,997 | $29K | |
| 80359 | <1% | 5,666 | $28K | |
| 84460 | <1% | 5,457 | $28K | |
| 87660 | <1% | 1,909 | $27K | |
| 87510 | <1% | 1,909 | $27K | |
| 87480 | <1% | 1,909 | $27K | |
| 83735 | <1% | 5,416 | $27K | |
| 80361 | <1% | 5,373 | $26K | |
| 85610 | <1% | 6,514 | $26K | |
| 86431 | <1% | 4,828 | $26K | |
| 88141 | <1% | 2,965 | $25K | |
| 80335 | <1% | 4,944 | $25K | |
| 86735 | <1% | 2,869 | $25K | |
| 83921 | <1% | 1,038 | $24K | |
| 86141 | <1% | 2,275 | $24K | |
| 84481 | <1% | 2,592 | $24K | |
| 82950 | <1% | 3,993 | $23K | |
| 86334 | <1% | 852 | $23K | |
| 85730 | <1% | 3,599 | $23K | |
| 82533 | <1% | 1,201 | $23K | |
| 87350 | <1% | 2,048 | $21K | |
| 80076 | <1% | 2,836 | $21K | |
| 82785 | <1% | 1,631 | $21K | |
| 82248 | <1% | 4,138 | $21K | |
| 86665 | <1% | 491 | $20K | |
| 80346 | <1% | 4,019 | $19K | |
| 82105 | <1% | 2,817 | $19K | |
| 83690 | <1% | 3,081 | $18K | |
| 87338 | <1% | 2,179 | $18K | |
| 80353 | <1% | 3,712 | $18K | |
| 86707 | <1% | 1,725 | $18K | |
| 84480 | <1% | 3,090 | $18K | |
| 84550 | <1% | 3,480 | $18K | |
| 87563 | <1% | 766 | $17K | |
| 83090 | <1% | 889 | $17K | |
| 88112 | <1% | 673 | $17K | |
| 86361 | <1% | 686 | $16K | |
| 83993 | <1% | 1,359 | $16K | |
| 86364 | <1% | 1,851 | $15K | |
| 86901 | <1% | 3,374 | $14K | |
| 84156 | <1% | 2,704 | $14K | |
| 82550 | <1% | 2,654 | $13K | |
| 82150 | <1% | 2,622 | $13K | |
| 83880 | <1% | 383 | $13K | |
| 87177 | <1% | 1,061 | $13K | |
| 86850 | <1% | 2,128 | $12K | |
| 86255 | <1% | 1,794 | $12K | |
| 84479 | <1% | 3,518 | $12K | |
| 86039 | <1% | 2,228 | $12K | |
| 82565 | <1% | 2,222 | $11K | |
| 86147 | <1% | 499 | $11K | |
| 82977 | <1% | 2,152 | $11K | |
| 86900 | <1% | 2,470 | $11K | |
| 86705 | <1% | 1,027 | $11K | |
| 82947 | <1% | 1,987 | $10K | |
| 80324 | <1% | 1,968 | $10K | |
| 84100 | <1% | 1,945 | $10K | |
| 87075 | <1% | 829 | $9K | |
| 80323 | <1% | 2,001 | $9K | |
| 86618 | <1% | 475 | $9K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 331 | $9K |
| 86225 | <1% | 1,669 | $9K | |
| 84520 | <1% | 1,739 | $9K | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 422 | $9K |
| 81003 | <1% | 4,021 | $8K | |
| 80178 | <1% | 1,027 | $7K | |
| 86146 | <1% | 324 | $7K | |
| 84165 | <1% | 897 | $7K | |
| 84425 | <1% | 461 | $7K | |
| 86671 | <1% | 760 | $7K | |
| 87329 | <1% | 403 | $7K | |
| 87209 | <1% | 1,058 | $6K | |
| 82274 | <1% | 1,701 | $6K | |
| 83020 | <1% | 381 | $6K | |
| 82672 | <1% | 229 | $6K | |
| 82951 | <1% | 769 | $5K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 63 | $5K |
| 84155 | <1% | 1,049 | $5K | |
| 86664 | <1% | 283 | $5K | |
| 83021 | <1% | 230 | $5K | |
| 87205 | <1% | 1,370 | $5K | |
| 84703 | <1% | 2,307 | $5K | |
| 86481 | <1% | 93 | $5K | |
| 82140 | <1% | 242 | $5K | |
| 86617 | <1% | 141 | $5K | |
| 86036 | <1% | 598 | $4K | |
| 87449 | <1% | 777 | $4K | |
| 87324 | <1% | 408 | $4K | |
| 83615 | <1% | 771 | $4K | |
| 85018 | <1% | 1,871 | $4K | |
| 87902 | <1% | 13 | $4K | |
| 87625 | <1% | 71 | $4K | |
| 82247 | <1% | 728 | $4K | |
| 80164 | <1% | 321 | $3K | |
| 87045 | <1% | 407 | $3K | |
| 80358 | <1% | 775 | $3K | |
| 82024 | <1% | 64 | $3K | |
| 87427 | <1% | 229 | $3K | |
| 82040 | <1% | 620 | $3K | |
| 85014 | <1% | 1,516 | $3K | |
| 82310 | <1% | 564 | $3K | |
| 85041 | <1% | 892 | $3K | |
| 80365 | <1% | 687 | $3K | |
| 80051 | <1% | 411 | $3K | |
| 84075 | <1% | 522 | $3K | |
| 82330 | <1% | 486 | $2K | |
| 80354 | <1% | 1,685 | $2K | |
| 86258 | <1% | 187 | $2K | |
| 84446 | <1% | 112 | $2K | |
| 84590 | <1% | 144 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 40 | $2K |
| 85613 | <1% | 228 | $2K | |
| 84630 | <1% | 229 | $2K | |
| 85048 | <1% | 455 | $1K | |
| 85045 | <1% | 438 | $1K | |
| 83498 | <1% | 37 | $1K | |
| 80197 | <1% | 126 | $1K | |
| 87101 | <1% | 132 | $1K | |
| 82955 | <1% | 90 | $1K | |
| 86008 | <1% | 61 | $1K | |
| 80356 | <1% | 267 | $1K | |
| 82378 | <1% | 40 | $1K | |
| 86381 | <1% | 80 | $973.94 | |
| 84466 | <1% | 67 | $828.45 | |
| 80320 | <1% | 206 | $767.65 | |
| 82172 | <1% | 42 | $736.56 | |
| 81596 | <1% | 14 | $710.22 | |
| 87046 | <1% | 236 | $702.66 | |
| 81329 | <1% | 12 | $670.64 | |
| 86304 | <1% | 25 | $636.75 | |
| 86709 | <1% | 63 | $605.90 | |
| 84681 | <1% | 24 | $547.92 | |
| 82952 | <1% | 363 | $518.77 | |
| 82677 | <1% | 25 | $453.16 | |
| 86256 | <1% | 50 | $447.36 | |
| 83521 | <1% | 36 | $447.20 | |
| 84482 | <1% | 74 | $428.64 | |
| 82465 | <1% | 89 | $407.94 | |
| 84163 | <1% | 28 | $364.00 | |
| 87076 | <1% | 29 | $346.80 | |
| 85007 | <1% | 237 | $342.85 | |
| 81015 | <1% | 161 | $326.48 | |
| 82103 | <1% | 24 | $315.60 | |
| 80345 | <1% | 80 | $283.22 | |
| 80177 | <1% | 27 | $280.59 | |
| 86231 | <1% | 38 | $270.25 | |
| 86593 | <1% | 66 | $255.92 | |
| 82390 | <1% | 29 | $246.50 | |
| 86162 | <1% | 12 | $242.16 | |
| 86015 | <1% | 52 | $221.12 | |
| 86336 | <1% | 28 | $188.93 | |
| 81025 | <1% | 90 | $183.62 | |
| 85379 | <1% | 13 | $145.08 | |
| 83630 | <1% | 24 | $130.80 | |
| 87255 | <1% | 12 | $85.32 | |
| 82340 | <1% | 12 | $79.68 | |
| 84300 | <1% | 14 | $73.22 | |
| 84133 | <1% | 12 | $62.76 | |
| 86308 | <1% | 12 | $58.56 | |
| 85004 | <1% | 12 | $39.12 | |
| 80364 | <1% | 26 | $9.72 | |
| 80326 | <1% | 26 | $9.72 | |
| 80337 | <1% | 26 | $9.72 | |
| 80367 | <1% | 26 | $9.72 | |
| 80321 | 0% | 1,456 | $0.00 | |
| 80355 | 0% | 653 | $0.00 | |
| 80366 | 0% | 94 | $0.00 | |
| 80369 | 0% | 38 | $0.00 | |
| 80339 | 0% | 21 | $0.00 | |
| 80360 | 0% | 22 | $0.00 | |
| 82166 | 0% | 13 | $0.00 | |
| 86317 | 0% | 160 | $0.00 | |
| 80368 | 0% | 356 | $0.00 | |
| 86021 | 0% | 505 | $0.00 | |
| 36415 | Collection of venous blood by venipuncture | 0% | 3,516 | $0.00 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 43 | $0.00 |
| 87147 | 0% | 142 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBOWLES, CHARLES (VICE PRESIDENT)
Parent organizationQUEST DIAGNOSTICS INCORPORATED
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.